Novo Nordisk ADR (NVO) concluded trading on Wednesday at a closing price of $120.93, with 4.11 million shares of worth about $497.38 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 30.12% during that period and on Wednesday the price saw a loss of about -0.43%. Currently the company’s common shares owned by public are about 3.38B shares, out of which, 3.38B shares are available for trading.
Stock saw a price change of 0.78% in past 5 days and over the past one month there was a price change of 14.64%. Year-to-date (YTD), NVO shares are showing a performance of 16.90% which increased to 70.77% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $67.66 but also hit the highest price of $124.76 during that period. The average intraday trading volume for Novo Nordisk ADR shares is 4.43 million. The stock is currently trading 4.62% above its 20-day simple moving average (SMA20), while that difference is up 11.97% for SMA50 and it goes to 28.47% higher than SMA200.
Novo Nordisk ADR (NYSE: NVO) currently have 3.38B outstanding shares and institutions hold larger chunk of about 9.14% of that.
The stock has a current market capitalization of $409.16B and its 3Y-monthly beta is at 0.41. PE ratio of stock for trailing 12 months is 44.77, while it has posted earnings per share of $2.70 in the same period. Its PEG reads 15.99 and has Quick Ratio of 0.64 while making debt-to-equity ratio of 0.25. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NVO, volatility over the week remained 2.46% while standing at 1.85% over the month.
Analysts are in expectations that Novo Nordisk ADR (NVO) stock would likely to be making an EPS of $0.78 in the current quarter, while forecast for next quarter EPS is $0.79 and it is $3.91 for next year. For the current quarter EPS, analysts have given the company a lowest target $0.77 which is $0.79 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $0.64 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 23.33% while it is estimated to increase by 20.10% in next year. EPS is likely to shrink at an annualized rate of 2.80% for next 5-years, compared to annual growth of 16.48% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on January 23, 2024 offering an Overweight rating for the stock and assigned a target price of $120 to it. On December 01, 2023, Cantor Fitzgerald Initiated their recommendations, while on October 02, 2023, Argus Initiated their ratings for the stock with a price target of $110. Stock get a Buy rating from HSBC Securities on July 14, 2023.
